Effect of ketogenic diets on insulin-like growth factor (IGF)-1 in humans: A systematic review and meta-analysis

被引:0
|
作者
Rajakumar, Gayathiri [1 ,2 ]
Cagigas, Maria Lastra [1 ,2 ]
Wang, Tian [1 ]
Pan, Angela Y. [1 ,2 ]
Pelaia, Tiana [1 ,2 ]
Fuller, Stephen J. [2 ,3 ]
Fontana, Luigi [1 ,4 ]
机构
[1] Univ Sydney, Charles Perkins Ctr, Sydney, NSW 2006, Australia
[2] Univ Sydney, Fac Med & Hlth, Sydney Med Sch, Nepean Clin Sch, Kingswood, NSW 2747, Australia
[3] Nepean Hosp, Dept Haematol, Kingswood, NSW 2747, Australia
[4] Royal Prince Alfred Hosp, Dept Endocrinol, Camperdown, NSW 2050, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
Ketogenic diet; Insulin-like growth factor 1; Glucose metabolism; Ageing; Cancer; IGF-BINDING PROTEINS; LIFE-SPAN; LUNG-CANCER; FACTOR-I; RESTRICTION; CALORIE; CHEMOTHERAPY; FEASIBILITY; MECHANISMS; RESISTANCE;
D O I
10.1016/j.arr.2024.102531
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
<bold>Background: </bold>Insulin-like growth factor (IGF)-1 plays a role in aging and cancer biology, with fasting known to reduce serum IGF-1 levels in human adults. However, the impact of ad libitum ketogenic diets (KDs) on IGF-1 levels remains unclear. <bold>Methods: </bold>Adhering to PRISMA guidelines, we conducted a meta-analysis of human trials by systematically searching Ovid, PubMed, Scopus, and CENTRAL Libraries until June 2023. Eligible studies prescribed KDs to adults of any health status, confirmed ketosis, and measured serum IGF-1. Protocols involving prescribed fasting or energy restriction were excluded. Mean differences (MD) and 95 % confidence intervals (CIs) were calculated longitudinally between pre- and post-intervention measurements for the KD groups. <bold>Results: </bold>Among twelve publications meeting the inclusion criteria, 522 individuals participated, with 236 completing KDs. The intervention duration ranged from 1 to 20 weeks. Pooled results from ten trials showed a significant reduction in serum IGF-1 levels post-intervention (MD: -24.9 ng/mL [95 % CI -31.7 to -18.1]; p<0.0001) with low heterogeneity across studies (I-2=27 %, p=0.19). KDs were also associated with significantly decreased fasting insulin (MD: -2.57 mU/L [95 % CI -4.41 to -0.74], p=0.006) and glucose (MD: -7.30 mg/dL [95 % CI -11.62 to -2.98], p=0.0009), although heterogeneity was significant. Subgroup analyses on study design, gender, dietary duration, and oncological status revealed no significant differences. <bold>Conclusion: </bold>Ad libitum KDs (>55 % fat) effectively induce ketosis and can lower serum IGF-1 by 20 %, fasting glucose by 6 % and insulin by 29 %. This clinically notable reduction in IGF-1 can be attained without the need for a prescribed fasting or severe calorie restriction regimen. Further investigation is warranted to explore the impact of KDs on ageing biomarkers and cancer management.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] The effects of lycopene supplementation on serum insulin-like growth factor 1 (IGF-1) levels and cardiovascular disease: A dose-response meta-analysis of clinical trials
    Xie, Zhihong
    Yang, Feng
    COMPLEMENTARY THERAPIES IN MEDICINE, 2021, 56
  • [42] Function of insulin-like growth factor 1 receptor in cancer resistance to chemotherapy (Review)
    Yuan, Jingsheng
    Yin, Zhijie
    Tao, Kaixiong
    Wang, Guobing
    Gao, Jinbo
    ONCOLOGY LETTERS, 2018, 15 (01) : 41 - 47
  • [43] Suitability of Insulin-Like Growth Factor 1 (IGF1) as a Measure of Relative Growth Rates in Lingcod
    Andrews, Kelly S.
    Beckman, Brian R.
    Beaudreau, Anne H.
    Larsen, Donald A.
    Williams, Greg D.
    Levin, Phillip S.
    MARINE AND COASTAL FISHERIES, 2011, 3 (01): : 250 - 260
  • [44] Targeting of the IGF (Insulin-like Growth Factor) route in pulmonary oncology
    Moro-Sibilot, D.
    Coudurier, M.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2009, 65 : S80 - S83
  • [45] The Role of Insulin-like Growth Factor-1 (IGF-1) in the Control of Neuroendocrine Regulation of Growth
    Al-Samerria, Sarmed
    Radovick, Sally
    CELLS, 2021, 10 (10)
  • [46] Insulin-like growth factor 1 (IGF1) polymorphism is associated with Alzheimer's disease in Han Chinese
    Wang, Wei
    Yu, Jin-Tai
    Tan, Lan
    Liu, Qiu-Yan
    Wang, Hui-Fu
    Ma, Xiao-Ying
    NEUROSCIENCE LETTERS, 2012, 531 (01) : 20 - 23
  • [47] Peripheral insulin-like growth factor 1 in bipolar disorder
    da Silva, Emily G.
    Pfaffenseller, Bianca
    Walz, Julio
    Stertz, Laura
    Fries, Gabriel
    Rosa, Adriane R.
    Magalhaes, Pedro V.
    PSYCHIATRY RESEARCH, 2017, 250 : 30 - 34
  • [48] Serum insulin-like growth factor 1 in the aging horse
    Lygren, Tone
    Hansen, Sanni
    Langberg, Henning
    Fjeldborg, Julie
    Jacobsen, Stine
    Nielsen, Mette O.
    Schjerling, Peter
    Markussen, Bo
    Thomsen, Preben D.
    Berg, Lise C.
    VETERINARY CLINICAL PATHOLOGY, 2014, 43 (04) : 557 - 560
  • [49] THE ROLE OF INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) IN BRAIN DEVELOPMENT, MATURATION AND NEUROPLASTICITY
    Dyer, Adam H.
    Vahdatpour, Cyrus
    Sanfeliu, Albert
    Tropea, Daniela
    NEUROSCIENCE, 2016, 325 : 89 - 99
  • [50] Salivary and serum insulin-like growth factor (IGF-1) assays in anorexic patients
    Paszynska, Elzbieta
    Dmitrzak-Weglarz, Monika
    Slopien, Agnieszka
    Tyszkiewicz-Nwafor, Marta
    Rajewski, Andrzej
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2016, 17 (08) : 615 - 621